Alumis Inc. ( (ALMS) ) has released its Q3 earnings. Here is a breakdown of the information Alumis Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alumis Inc., a clinical-stage biopharmaceutical company, is focused on developing next-generation targeted therapies for immune-mediated diseases. The company is advancing its pipeline with significant progress in its clinical trials, particularly for its oral TYK2 inhibitors aimed at treating conditions like plaque psoriasis and systemic lupus erythematosus.
In its third-quarter 2025 financial report, Alumis highlighted key milestones, including the publication of positive Phase 2 trial results for envudeucitinib in a leading dermatology journal and the promising preclinical data for A-005, a CNS-penetrant TYK2 inhibitor. The company also showcased lonigutamab’s potential in treating thyroid eye disease, with encouraging safety and efficacy outcomes from early-stage studies.
Financially, Alumis reported a net loss of $110.8 million for the quarter, an increase from the previous year, driven by higher research and development expenses and costs related to its merger with ACELYRIN. Despite these losses, the company maintains a strong cash position with $377.7 million in cash, cash equivalents, and marketable securities, which is expected to support its operations into 2027.
Looking ahead, Alumis is poised for significant developments with anticipated data readouts from its ongoing clinical trials in 2026. The company remains committed to leveraging its precision immunology platform to transform treatment options for patients with immune-mediated diseases.